Patents by Inventor Kaiyan Wang

Kaiyan Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Application of naringin combined with rapamycin in preparation of medications for treating hyperlipidemia
    Patent number: 12778974
    Abstract: The present disclosure relates to the field of medicine and specifically to an application of naringin combined with rapamycin in preparation of medications for treating hyperlipidemia. Naringin achieves anti-inflammatory and lipid-lowering effects by inhibiting the formation of oxLp-NLRP3 complexes. The present disclosure has been substantiated through cellular experiments and animal experiments, it demonstrates that naringin effectively intervenes in the early progression of hyperlipidemia by neutralizing oxLp and inhibiting the formation of oxLp-NLRP3 complexes. The inhibitory effect of naringin on oxLp-NLRP3 complexes contributes to unleashing the therapeutic potential of rapamycin in hyperlipidemia, providing a combined strategy for the prevention and treatment of hyperlipidemia-related diseases in clinical applications.
    Type: Grant
    Filed: December 28, 2023
    Date of Patent: November 3, 2026
    Inventors: Lina Niu, Kaiyan Wang, Weiwei Yu, Wen Qin, Yuxuan Ma, Chen Lei
  • Application of Naringin Combined with Rapamycin in Preparation of Medications for Treating Hyperlipidemia
    Publication number: 20240122956
    Abstract: The present disclosure relates to the field of medicine and specifically to an application of naringin combined with rapamycin in preparation of medications for treating hyperlipidemia. Naringin achieves anti-inflammatory and lipid-lowering effects by inhibiting the formation of oxLp-NLRP3 complexes. The present disclosure has been substantiated through cellular experiments and animal experiments, it demonstrates that naringin effectively intervenes in the early progression of hyperlipidemia by neutralizing oxLp and inhibiting the formation of oxLp-NLRP3 complexes. The inhibitory effect of naringin on oxLp-NLRP3 complexes contributes to unleashing the therapeutic potential of rapamycin in hyperlipidemia, providing a combined strategy for the prevention and treatment of hyperlipidemia-related diseases in clinical applications.
    Type: Application
    Filed: December 28, 2023
    Publication date: April 18, 2024
    Applicant: AIR FORCE MEDICAL UNIVERSITY
    Inventors: Lina Niu, Kaiyan Wang, Weiwei Yu, Wen Qin, Yuxuan Ma, Chen Lei